Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Cancer Discov. 2019 Oct 28;10(1):54–71. doi: 10.1158/2159-8290.CD-19-1167

Figure 4.

Figure 4.

Activity of MRTX849 in Lung and Colon Cancer Patients

(A) Pretreatment and 6-week scans of a heavily pretreated patient with a KRASG12C mutation-positive lung adenocarcinoma indicating 33% reduction of target lesions. Patient continues on study. The top panels show a coronal view and bottom panels an axial view of computed tomography (CT) chest images prior to MRTX849 treatment (left) and after two cycles of MRTX849 treatment (right).

(B) Baseline, 6-week (Cycle 2) and 12-week (Cycle 4) scans of a patient with a KRASG12C mutation-positive colon adenocarcinoma. Partial response confirmed at Cycle 4 and patient continues on study. Four lesions (TL1–4) are shown with axial views of CT images prior to MRTX849 treatment (top), after two cycles of MRTX849 treatment (center), and after four cycles of MRTX849 treatment (bottom).